Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Electrocardiography wikipedia , lookup
Cardiovascular disease wikipedia , lookup
Hypertrophic cardiomyopathy wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Heart failure wikipedia , lookup
Cardiac surgery wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Coronary artery disease wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
Katie DePlatchett M.D. AM Report June 29, 2010 Elevated Pulmonary Artery pressure Secondary R Ventricular failure Mean Pulm Artery Pressure of >25mmHg at rest Pulmonary capillary wedge pressure (PCWP) <15mmHG ◦ Diagnosed by Right Heart Catherization (RHC) Ohm’s Law: P=QxR Pa- Pv = CO (right sided) x PVR Pa = (CO x PVR) + PCWP PVR: occlusion of small arterioles, hypoxic vasoconstriction CO: congenital defects (shunts), cirrhosis PCWP: systolic HF, valvular dx intimal hyperplasia and fibrosis, medial hypertrophy, and in situ thrombi of the small pulmonary arteries and arterioles Previously idiopathic PAH vs secondary PAH Amended to groups (Group 1-5) based on etiology Idiopathic Heritable Disease which localize to small pulm arterioles ◦ connective tissue disease, HIV, portal htn, chronic hemolytic anemia, congenital Drug or toxin induced ◦ amphetamines, cocaine, appetite suppressants (fen-fen), chemotherapies, St. John’s wort, SSRIs PH secondary to L heart disease (G2) PH secondary to lung dx or hypoxemia (Group 3) ◦ systolic, diastolic, valvular dx ◦ COPD, ILD, OSA, Hypoventilation Chronic thromboembolic PH (Group 4) PH due to “unclear multifactorial mechanisms” (Group 5) ◦ Heme, systemic (sarcoidosis), metabolic (glycogen storage dx) Increased intensity of pulmonic component of 2nd heart sound or split P2 Systolic ejection murmur over LSB Diastolic murmur over LSB (d/t pulm regurg) R-sided S3 or S4 Elevated JVP Peripheral edema Hepatomegaly, ascites CXR: enlargement of the central pulmonary arteries with attenuation of the peripheral vessels ECG R heart strain, RAD Echo estimate the pulmonary artery systolic pressure and to assess right ventricular size, thickness, and function ◦ PH is likely if the PASP is >50 and the TRV is >3.4 Labs: HIV, LFTs, ANA, RF, ANCA, ? evidence of chronic hemolytic anemia PFTs to identify and characterize underlying lung disease that may be contributing Overnight oximetry to assess nocturnal oxyhemoglobin desaturation Sleep study for eval of OSA V/Q scan for chronic thromboemboli Right Heart Catherization ◦ necessary to confirm the diagnosis of PH and accurately determine the severity of the hemodynamic derangements 6 min walk ◦ To determine functional status ◦ Assist with prognosis ◦ Some cases are exercised induced Class: I Ordinary physical activity does not cause undue fatigue or dyspnea, chest pain, or heart syncope. Class II: Slight limitation of physical activity. Ordinary physical activity results in undue fatigue or dyspnea, chest pain, or heart syncope. Class III: Less than ordinary physical activity causes undue fatigue or dyspnea, chest pain, or heart syncope. Class IV: Inability to carry on any physical activity without symptoms. Usually manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Oxygen Diuretics Anticoagulation for groups 1 & 4 ◦ intrapulmonary thrombosis & thromboembolism, due to sluggish pulmonary blood flow, dilated right heart chambers, venous stasis, and a sedentary lifestyle ◦ Warfarin therapy w/ INR target of 2.0 Exercise…get off that couch! ◦ Improved functional status Phosphodiesterase 5 inhibitors (sildenafil) ◦ prolong the vasodilatory effect of nitric oxide ◦ SUPER trial, improved HD & exercise capacity, no change in mortality ◦ Class III Endothelian receptor antagonist (Tracleer) ◦ Endothelin-1 is a potent vasoconstrictor and smooth muscle mitogen ◦ BREATHE-1 trial, improved symptoms, the six-minute walking distance, and the WHO functional class ◦ Class II & III CCB ◦ Class II & III Vasoreactivity testing during RHC ◦ Measures HD response to nitric oxide or Flolan ◦ If Pulm artery pressure decreases by 10mm Hg & is <40mm Hg w/o a significant change in CO, then trial of CCB (Diltiazem 120mg daily & titrate) ◦ If negative (no response) Prostanoids (Flolan, Remodulin) Prostanoids = prostacyclins ◦ Potent vasodialator & inhibitor of platet aggregation Symptomatic IPAH w/o treatment have a median survival of ~ 3 years Symptomatic w/ PAH that is associated with another disease generally have a worse prognosis Severe PAH or right CHF median survival of 1 year w/o treatment